The effect of biosynthetic human growth hormone (BSHGH) on postoperative protein and energy metabolism has been studied in patients who had major gastrointestinal surgery. Seven patients received placebo and seven patients received BSHGH, 0.1 mg/kg/24 h, for the first six postoperative days. Mean total nitrogen excretion was significantly lower with BSHGH (31.5 ± 2.4 g N) (2287 ± 160 mmol) than with placebo (42.7 ± 3.1 g N) (3049 ± 219 mmol) over the 6-day study period. The mean daily measured energy expenditure over days 3-6 was higher with BSHGH (31.3 ± 1.8 kcal/kg LBM/24 h) (131 ± 7 kJ/kg LBM/24 h) than with placebo (27.6 ± 0.8 kcal/kg LBM/24 h) (114 ± 2 kJ/kg LBM/24 h). Fat oxidation with BSHGH (2.05 ± 0.26 mg/kg LBM/24 h) was greater than with placebo (1.5 ± 0.17 mg/kg LBM/24 h) and protein oxidation was less with BSHGH (0.68 ± 0.07 g/kg LBM/24 h) than with placebo (0.9 ± 0.09 g/kg LBM/24 h) on days 1-6. Postoperative nitrogen turnover (BSHGH 943 ± 174 mg N/kg LBM/24 h, placebo 557 ± 50 mg N/kg LBM/24 h) (BSHGH 67 ± 13 mmol/kg LBM/24 h, placebo 40 ± 4 mmol/kg LBM/24 h), protein synthesis (BSHGH 5.31 ± 1.09 g prot/kg LBM/24 h, placebo 2.54 ± 0.33 g prot/kg LBM/24 h) and protein breakdown (BSHGH 5.90 ± 1.09 g prot/kg LBM/24 h, placebo 3.48 ± 0.31 g prot/kg LBM/24 h) were greater with BSHGH. On the first postoperative day serum insulin and blood glucose levels were higher with BSHGH than with placebo, and on days 4 and 7 serum somatomedin-C levels were significantly elevated. This study shows that BSHGH alters postoperative protein and energy metabolism by reducing protein oxidation and increasing fat oxidation with raised rates of whole body nitrogen turnover. 
blood glucose levels were higher with BSHGH than with placebo, and on days 4 and 7 serum somatomedin-C levels were significantly elevated. This study shows that BSHGH alters postoperative protein and energy metabolism by reducing protein oxidation and increasing fat oxidation with raised rates of whole body nitrogen turnover. In the preoperative studies, patients were allowed fluids by mouth, to provide 400 kcal/24 h with negligible nitrogen intake. After operation they received a regimen of saline and 5% dextrose solution providing 400 kcal/24 h (1675 kJ/24 h). Water by mouth was introduced when indicated and dietary intake was begun after the sixth day.
Blood samples were drawn for substrate and hormone levels on the control day before operation and on the first, fourth, seventh, and ninth postoperative days between 8:00 A.M. and 9:00 A.M.
Indirect calorimetry was done before operation and on the first 6 postoperative days between 10:00 A.M. and 12:00 P.M. Resting energy expenditure (REE) was determined from oxygen consumption and carbon dioxide production, using Weir's formula.'2 Oxygen and carbon dioxide concentration were measured with paramagnetic and infrared analysers, respectively, gas flow was measured by a Fleisch pneumatochograph incorporated in a mobile system giving a visual display and a continuous printout ofresults (Calostar, Fenyves & Gut, Basel, Switzerland'3). Rates of substrate oxidation were calculated from oxygen consumption, carbon dioxide production, and urinary nitrogen excretion by MacHattie's formulae. '4 Urine for total nitrogen excretion was collected throughout the study period. Total nitrogen was measured by a semiautomated Kjeldahl technique. Nitrogen turnover was measured before operation and on the third to fourth postoperative days using a primed continuous infusion of '5N glycine for 24 hours. ' (Fig. 1) . Carbohydrate oxidation (BSHGH 2.10 ± 0.36 g/kg LBM/24 h and placebo 2.09 ± 0.36) was similar and corresponded to dextrose infusion rates of 2.11 ± 0.21 g/kg LBM/24 h for BSHGH and 2.12 ± 0.17 for placebo; protein oxidation (calculated from nitrogen excretion, Fig. 2 ) was significantly lower with BSHGH than with placebo (0.68 ± 0.07 g/kg LBM/24 h and placebo 0.92 ± 0.09, mean for days 1-6, p < 0.05).
Whole body nitrogen turnover, protein synthesis, and breakdown results are shown in Table 3 . All values were similar in the preoperation period but after operation, nitrogen turnover, protein synthesis, and breakdown rates were significantly higher in the group receiving BSHGH. In five patients receiving placebo and six patients receiving BSHGH in whom nitrogen turnover was measured before and after operation, turnover decreased to a mean of 75% (range: 61-87%) of control in those with placebo, whereas with BSHGH turnover in- Nitrogen balance is an index of net whole body protein balance. If whole body nitrogen turnover is measured, nitrogen intake and excretion can be used to derive rates of whole body protein synthesis and breakdown.'6 The '5N from glycine has been shown to be widely distributed among the other amino acids,'8 and although growth hormone has been shown to decrease the plasma level of most amino acids'9 there does not appear to be a specific effect on glycine metabolism. In the absence ofevidence for a specific metabolic pathway between glycine and urea (which is affected by growth hormone to produce a decrease in transfer of the amino nitrogen of glycine to urea), the decrease in 15N enrichment of urinary urea from which the increase in nitrogen turnover with growth hormone is derived is interpreted as being an effect on whole body protein metabolism and not a specific effect of growth hormone on glycine metabolism.
The improved nitrogen balance seen with administration of growth hormone occurs with a postoperative protein synthesis rate of 209% ofthe corresponding synthetic rate for placebo and a breakdown rate of 170% of placebo, indicating a relative increase in synthesis to breakdown of 39%. In the absence of exogenous protein intake, the amino acids for protein synthesis will be derived from breakdown and the expression ofsynthesis as a percentage of breakdown will give a value for the recycling of protein and, hence, the efficiency of protein metabolism. After operation there was a decrease in recycling of protein of 12% compared with before operation in the placebo group and an increase of 5% with growth hormone, there being a 17% improvement in the efficiency of protein metabolism after surgery when growth hormone is given.
The diversion of amino acids as potential gluconeogenic substrates from oxidative to synthetic pathways when growth hormone is given results in a reduction ofa mean of 51 kcal/d (214 kJ/d) derived from protein oxidation. The increased energy production of 264 kcal/d (1 105 kJ/d) from fat oxidation is in excess of that required to compensate for the shortfall from protein oxidation by a mean of 213 kcal/d (892 kJ/d). It is likely that this excess in oxidation of fat is a result of the specific action of growth hormone on increasing lipolysis and free fatty acid oxidation.'9 This is seen as an overall increase in energy expenditure, most notably in the last 4 days of the study.
A diabetogenic effect of growth hormone producing increases in blood glucose and serum insulin has been described'9 and is confirmed in this study. Serum levels of growth hormone, somatomedin-C, and insulin were all affected by growth hormone administration. Growth hormone stimulates secretion of somatomedin-C from the liver20 and the gradually increasing levels of somatomedin-C during growth hormone administration suggest a direct action ofgrowth hormone. Insulin levels are highest when blood glucose peaks and decreases as the glucose levels fall, suggesting that insulin levels are not primarily affected by growth hormone administration but relate to the blood glucose level. Because both somatomedin-C and insulin are capable ofincreasing rates of protein synthesis it is not possible to determine in this study if the elevated levels of either hormone, or growth hormone itself, are responsible for the raised rate of protein synthesis.
These studies were designed to investigate the effect of growth hormone administration on postoperative metabolism and have clearly demonstrated improved protein economy and increased fat oxidation in patients with minimal nutritional intake. The suggestion that somatomedin-C is a mediator ofthe protein responses is worthy of further investigation; however, this will only be possible if somatomedins can be synthesized and produced in sufficient quantites by recombinant DNA technology. This study has not specifically studied clinical outcome but it is unlikely that this will be affected by these metabolic changes. The importance of the data obtained here is to provide information that can be used to evaluate the effect of growth hormone on nutrient (particularly intravenous) utilization in not only producing more efficient use of expensive materials but perhaps in reducing the quantities of nutrients that require administration, thus allowing greater use of peripheral (as opposed to central) vein feeding.
